Precision moves in MASH: a new era of tailored therapies
This Nature review maps the current and future treatment landscape for metabolic dysfunction‑associated steatohepatitis (MASH), noting that recent approvals (resmetirom and semaglutide) mark an inflection point for non‑cirrhotic disease and fibrosis. It highlights MASH heterogeneity with liver‑centric and cardiometabolic subsets, arguing that optimal therapy will need stratified or combinatorial approaches that target metabolic dysfunction, fibrogenesis, inflammation, and the gut–liver axis, alongside lifestyle modification. Advances in disease phenotyping and biomarkers are seen as enabling a shift toward personalized, mechanism‑driven therapy.
